Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib/II Trial to Evaluate Safety and Efficacy of Oral Ixazomib in the Prophylaxis of Chronic Graft-versus-host Disease.

NCT03225417 is registered in ClinicalTrials.gov with Fundación Pública Andaluza para la gestión de la Investigación en Sevilla as lead sponsor.

NCT NCT03225417
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03225417 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib/II Trial to Evaluate Safety and Efficacy of Oral Ixazomib in the Prophylaxis of Chronic Graft-versus-host Disease.
Lead sponsor
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
May 16, 2017
Completion date
December 31, 2024
Enrollment
142 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

hematopoietic stem cell transplantation, multiple myeloma